Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Net Income (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Net Income for 6 consecutive years, with -$12.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Income fell 119.11% to -$12.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$51.1 million, a 154.82% decrease, with the full-year FY2024 number at -$28.6 million, down 42.31% from a year prior.
  • Net Income was -$12.8 million for Q3 2025 at Inhibikase Therapeutics, down from -$10.8 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$2.6 million in Q2 2021 to a low of -$14.6 million in Q1 2025.
  • A 5-year average of -$6.3 million and a median of -$4.8 million in 2023 define the central range for Net Income.
  • Peak YoY movement for Net Income: plummeted 566.75% in 2021, then grew 18.57% in 2024.
  • Inhibikase Therapeutics' Net Income stood at -$5.0 million in 2021, then rose by 14.02% to -$4.3 million in 2022, then decreased by 1.58% to -$4.4 million in 2023, then tumbled by 193.6% to -$12.9 million in 2024, then increased by 1.24% to -$12.8 million in 2025.
  • Per Business Quant, the three most recent readings for IKT's Net Income are -$12.8 million (Q3 2025), -$10.8 million (Q2 2025), and -$14.6 million (Q1 2025).